← Back

Wire · opportunities

Merck axes $2.7B BTK inhibitor program after seeing phase 3 data

Published

18 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at fiercebiotech.com →

◆ Verified

Fusion42 · 18 November 2026 · Fusion42 review

Merck has discontinued its $2.7 billion BTK inhibitor nemtabrutinib program after phase 3 trial data indicated the treatment's risks may outweigh benefits for chronic lymphocytic leukemia and small lymphocytic lymphoma patients.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Your biotech oncology project just lost a major competitor in BTK inhibitors. If you develop alternative blood cancer treatments, this opens a window to capture orphaned patients and partners left by Merck's exit.

◆ Coverage

1 source · 18 Nov 2026

◆ Related on Wire

◆ Topics

Biotechclinical-trial-failureoncologyBTK-inhibitorMerckdrug-development